Back to Search Start Over

Defect engineering synergistically boosts the catalytic activity of Fe-MoO v for highly efficient breast mesh antitumor therapy.

Authors :
Yang W
Zhou C
He C
Yang Y
Aiyiti W
Xu L
Shuai C
Source :
Journal of colloid and interface science [J Colloid Interface Sci] 2025 Jan 15; Vol. 678 (Pt A), pp. 260-271. Date of Electronic Publication: 2024 Aug 25.
Publication Year :
2025

Abstract

The demand for breast mesh with antitumor properties is critical in post-mastectomy breast reconstruction to prevent local tumor recurrence. Molybdenum-based oxide (MoO <subscript>x</subscript> ) exhibits enzyme-like activities by catalyzing endogenous hydrogen peroxide to produce reactive oxygen species for inducing tumor cell apoptosis. However, its catalytic activity is limited by insufficient active sites. Herein, a defect engineering strategy is proposed to create redox nanozymes with multiple enzymatic activities by incorporating Fe into MoO <subscript>x</subscript> (Fe-MoO <subscript>v</subscript> ). Fe-MoO <subscript>v</subscript> is subsequently integrated into polycaprolactone (PCL) to fabricate breast meshes for establishing an enzyme-catalyzed antitumor platform. The doping of Fe into MoO <subscript>x</subscript> formed numerous defect sites, including oxygen vacancies (OV) and Fe substitution sites, synergistically boosting the binding capacity and catalytic activity of Fe-MoO <subscript>v</subscript> . Density functional theory calculations demonstrated that the outstanding peroxidase-like catalytic activity of Fe-MoO <subscript>v</subscript> resulted from the synergy between OV and Fe sites. Additionally, OV contributes to the localized surface plasmon resonance effect, enhancing the photothermal capability of the PCL/Fe-MoO <subscript>v</subscript> mesh. Upon near-infrared laser exposure, the catalytic activity of the PCL/Fe-MoO <subscript>v</subscript> mesh is further improved, leading to increased generation of reactive oxygen species and enhanced antitumor efficacy, achieving 86.7% tumor cell mortality, a 264% enhancement compared to the PCL/MoO <subscript>x</subscript> mesh.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2024. Published by Elsevier Inc.)

Details

Language :
English
ISSN :
1095-7103
Volume :
678
Issue :
Pt A
Database :
MEDLINE
Journal :
Journal of colloid and interface science
Publication Type :
Academic Journal
Accession number :
39197369
Full Text :
https://doi.org/10.1016/j.jcis.2024.08.195